medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2010, Number 2

<< Back Next >>

Rev Invest Clin 2010; 62 (2)

Estatinas en la prevención secundaria de enfermedad vascular cerebral

Cantú C, Villarreal J, Barinagarrementeria F, Ruiz-Sandoval JL, Arauz A, Leyva A, Murillo L, Fernández-Vera JA, Amaya LE, Venegas A, Merino JG, Romano J

Language: Spanish
References: 34
Page: 162-169
PDF size: 213.56 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Amarenco P, Steg PG. The paradox of cholesterol and stroke. Lancet 2007; 370: 1803-4.

  2. Iso H, Jacobs DR Jr, Wentworth D, et al. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989; 320: 904-10.

  3. Horenstein RB, Smith DE, Mosca L. Cholesterol predicts stroke mortality in the Women’s Pooling Project. Stroke 2002; 33: 1863-8.

  4. Zhang X, Patel A, Horibe H, et al. Asia Pacific Cohort Studies Collaboration. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol 2003; 32: 563-72.

  5. Kurt T, Everett BM, Buring J, et al. Lipid levels and the risk of ischemic stroke in women. Neurology 2007; 68: 556-62.

  6. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.

  7. Rpsenson RS, Tagney ChC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998; 279: 1643-50.

  8. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol-lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.

  9. Plehn JF, Davis BR, Sacks FM, et al. Reduction of stroke incidence after myocardial infarction with pravastatin: The CARE study. Circulation 1999; 99: 216-23.

  10. White HD, Simes RJ, Anderson ML, et al. Pravastatin therapy and the risk of stroke (LIPID Study). N Engl J Med 2000; 343: 317-26.

  11. Waters DD, Schwartz GG, Olsson AG, Zeiher A, Oliver MF, Ganz P, et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction. A myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) substudy. Circulation 2002; 106: 1690-5.

  12. Heart Protection Study Collaborative Group. Effects of cholesterol- lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrobascular disease or other high-risk conditiones. Lancet 2004; 363: 757-67.

  13. Waters DD, LaRosa JC, Barter P, Fruchart JC, Gotto AM Jr, Carter R, et al. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (Treating to New Targets) study. J Am Coll Cardiol 2006; 48: 1793-9.

  14. Sever PS, Dahlof B, Poulter NR, et al., for ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo- Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.

  15. Colhoun HM, Betteridge DJ, Durrington PN, et al., for CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo- controlled trial. Lancet 2004; 364 :685-96.

  16. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto JM Jr, Kastelei JJP, et al., for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated Creactive protein (JUPITER Study). N Engl J Med 2008; 359: 2195-207.

  17. Amarenco P, Labreuche J, Lavallée Ph, Touboul P-J. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004; 35: 2902-9.

  18. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009; 8: 453-63.

  19. Amarenco P, Bogousslavsky J, Callahan A, et al., for the SPARCL investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-59.

  20. Blanco M, Nombela F, Castellanos M, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007; 69: 904-10.

  21. Colivicchi F, Bassi A, Santini M, et al. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 2007; 38: 2652-7.

  22. Chaturvedi S, Zivin J, Breazna A, et al., for the SPARCL Investigators. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack. Neurology 2009; 72: 688-94.

  23. Goldstein LB, Amarenco P, LaMonte M, et al on behalf of the SPARCL Investigators. Relative effects of statin therapy on stroke and cardiovascular events in men and women: Secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Stroke 2008; 39: 2444-8.

  24. Sillesen H, Amarenco P, Hennerici MG, et al. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial. Stroke 2008; 39: 3297-302.

  25. Goldstein LB, Amarenco P, Szarek M, et al., on behalf of the SPARCL Investigators. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial. Stroke 2008 38; 3198- 204.

  26. Goldstein LB, Amarenco P, Szarek M, et al., on behalf of the SPARCL Investigators. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2008; 70: 2364-70.

  27. Vergouwen MDI, de Haan RJ, et al. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke 2008; 39: 497-502.

  28. Law M, Rudnicka AR. Statin Safety: A Systematic Review. Am J Cardiol 2006; 97(Suppl.): 52C-60C.

  29. Lindenstrom E, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: The Copenhagen City Heart Study. Stroke 1994; 309: 11-15.

  30. Wannamethee SG, Shaper AG, Ebrahim S. HDL cholesterol, total cholesterol, and the risk of stroke in middle-aged British men. Stroke 2000; 311: 882-8.

  31. Sacco RL, Benson RT, Kargman DE, Boden-Albala B, Tuck C, Lin I-F, et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly: The Northern Manhattan Stroke Study. JAMA 2001; 285: 2729-35.

  32. Koren-Morag N, Tanne D, Graff E, Goldbourt U, for the Bezafibrate Infarction Prevention Study Group. Low-and highdensity lipoprotein cholesterol and ischemic cerebrovascular disease. Arch Intern Med 2002; 162: 993-99.

  33. Tanne D, Koren-Morag N, Graff E, Goldbourt U, for the BIP Study Group. Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) registry. High triglycerides constitute and independent risk factor. Circulation 2001; 103: 2893-7.

  34. Ninomiya JK, L’Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004; 109: 42-6.




2020     |     www.medigraphic.com